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Abstract 
 The interplay between each of these stakeholder’s responsibilities and desires clearly has 
resulted in continued widespread use of natalizumab with substantial risks and an ongoing quest for 
better risk mitigation.  In the United States, regulatory actions codified the process of risk acceptance –
and risk transfer- by escalating monitoring and information transfer to physicians and patients through 
Management of medication related risks is a core function of regulatory agencies such as the Food and 
Drug Administration (FDA), European Medicines Agency (EMA) and the medical community. The 
interplay between stakeholders in medicine, pharma, regulatory bodies, physicians and patients, 
sometimes has changed without overt review and discussion.  Such is the case for natalizumab, an 
important and widely used disease modifying therapy for multiple sclerosis. A rather silent but very 
considerable shift, effectively transferring increased risk for PML to the physicians and patients, has 
occurred in the past decade. We believe this changed risk should be clearly recognized and considered 
by all the stakeholders.  
History of natalizumab and Multiple Sclerosis 
The authors led the first assessment of the risk of natalizumab associated PML as an Independent 
Adjudication Committee organized to screen research patients exposed to natalizumab. Our assessment 
found  that the risk of PML ranged from 0.2 to 2.8 cases per 1000 exposed persons based on almost 18 
months exposure1.  During the initial adjudication process, it was understood that the 3 index cases 
were not the end but the beginning of PML cases associated  with natalizumab therapy.    
The authors have closely participated in the subsequent developments from positions in academia, 
government research and consultation with pharma. Following our assessment, the company received  
regulatory approval to re-market natalizumab.   Natalizumab is now  linked to over 645 confirmed PML 
cases, with a global risk estimate of  3.71 to 4.36 cases per 1000 patients exposed translating to about 
1/75 in the highest risk group developing PML2.  While the 77% survival with PML is much better than 
observed with PML historically, had the approximately 135 deaths attributed to this complication been 
clearly articulated at the hearing and the continued accrual of PML cases known, it may well have been 
more difficult for regulators to approve this therapy.  While the view in retrospect is clarifying, the view 
ahead has the benefit of a decade of experience that should be considered by the regulators and 
others to engage in an ongoing effote to make a valuable therapy for MS safer.  
Natalizumab for other diseases:  same drug, different outcomes 
The dynamics of therapies moving into practice are influenced by multiple factors. Natalizumab’s 
divergent trajectory for use in MS as compared to inflammatory bowel disease (IBD) illustrates this 
point.  The same medication and risk of PML, when proposed for IBD was deemed unacceptable to 
European regulators primarily because the modest efficacy did not justify the risks of this drug for 
IBD.(EMA Doc Ref. EMA/530964/2007) In the US, the FDA deemed the drug approvable in 2008 for 
moderate to severe Crohn’s disease (CD) with similar monitoring to what is used for MS distribution, 
effectively shifting the responsibility for risk acceptance to physician and patients.  In contrast to the MS 
scenario, physicians and patients used natalizumab very sparingly in CD, resulting in only three cases of 
PML in the subsequent  decade.  This difference is not because IBD patients have a lower risk, but 
almost surely because so few patients have been exposed.  Another parallel example of a biologic with 
serious risk of PML occurred when cases were associated with prolonged use of efalizumab for 
psoriasis.3,4  While efalizumab’s risk estimate for PML is quite similar to natalizumab, efalizumab was 
voluntarily removed from the market because acceptable alternative therapies were available.(FDA, 
4/8/2009) These examples illustrate how similar risks can drive diametrically different regulatory and 
practice outcomes. 
Stakeholders in Medicine 
Pharma is established to grow investments in this industry through identification of markets where 
there is need and avenues to address the medical conditions that will be effective. Their large 
investments in developing therapies have been essential to generate progress in medicine and support 
large companies with an emphasis on financial gain. Profit motivation is constrained by regulatory 
oversight as well as the importance of a strong and positive public image that engenders respect and 
trust while avoiding   behaviors that could threaten unsustainable liability claims.  When pharma 
calculates that a therapy is meritorious, they must prove the efficacy and substantiate the probable risk 
through large labelling clinical trials to support marketing with an indication through governmental 
regulatory bodies.  
Regulatory agencies are organized to assure that therapies are effective for specific indications, while 
having an ethically acceptable balance of benefit to risks. When unanticipated toxicities emerge, the 
regulatory agencies receive harsh criticism and are held accountable. At the same time, these agencies 
experience constant pressure to speed approval from the medical community seeking new and better 
medications as well as pharma wishing to benefit from their investment in drug development .  In recent 
years, the FDA has responded to demands to speed the progress for critical therapies. A good example 
of this is the acceleration of HIV/AIDS therapies when this epidemic emerged.  However, unanticipated 
risks such as the emergence of PML after marketing approval for natalizumab are reminders to the 
regulatory agencies that great caution must be applied while introducing novel therapy.  
Physicians are gatekeepers for prescribed drugs.  They are trained to diagnose diseases and weigh 
evidence for efficacy and toxicity of possible treatments in light of the patient’s overall status when 
prescribing optimal therapy.  While holding the virtue of unfailing defense of their patient’s wellbeing, 
and hired by the patient to recommend wisely, physicians are challenged by lack of time, competing 
sources of information and pressures to offer cost effective strategies for their practice as well as their 
patients.   Complex discussions of risk may take much time and effort, and can even dissuade patients 
from therapies that many would consider optimal.     
Meanwhile, patients and their families deserve and expect to make the final choices of how they 
are to confront their medical conditions.  However, it is challenging to equip typical patients with 
enough information to allow them to ethically assume responsibility for difficult medical decisions. 
Conflicting opinions, typical in any complex issue, are confusing and stressful for patients who often 
default to their doctor’s recommendation while not fully considering the consequences of risks they are 
assuming. Much misinformation is commonly available and very often salient parts of information short 
circuit needed full consideration of options and risks.  At the same time, the impact of living with 
difficult conditions such as MS or IBD are powerful motivators to assume significant risks.    
the TOUCH (Tysabri Outreach Unified Commitment to Health©, Biogen) program.  This program limits 
prescribers to those with significant experience and training appropriate to prescribing a riskier 
medication, and requires monthly queries of patients seeking symptoms and reconfirming at least the 
acceptance of the potential complication of PML. Critically, the European experience where a standard 
risk mitigation program was not instituted, has resulted in no worse, and potentially superior outcomes 
with regard to PML incidence and survival.5 Thus, the merits of risk mitigation through programs such as 
TOUCH deserve scrutiny before they are adapted to other challenges in health care6.  We view this 
process as a formalized, tacit passing of responsibility of risk acceptance from regulatory to end users of 
therapy as an unproven approach. This has evolved over time in attempts to mitigate PML risk, while 
assuring that all parties remain informed.  
This outcome was not a foregone conclusion given these risks and drugs. In the case of 
efalizumab, pharma and regulators agreed to remove the drug, effectively taking responsibility to 
protect patients from this risk. In the case of natalizumab for IBD, in Europe regulatory agencies again 
took the choice away for individuals by not approving the drug for IBD, while in the US FDA regulations  
appear to transfer decision about this risk through physicians to patients. Since the FDA decision 
supporting marketing natalizumab for MS, recognized PML risks have at least tripled, and in higher risk 
populations are an order of magnitude greater than originally estimated. Further, there have been 
multiple new therapies approved for multiple sclerosis.  
 The history of natalizumab therapy emphasizes the variable roles that have been assumed by 
stakeholders in the management of benefits and risks. It demonstrates how risk acceptance has been 
transferred from the industry and regulators to the physicians and patients. In many ways this system 
has worked extremely well, maintaining the availability of a sorely needed drug, while stimulating 
development of increasingly sophisticated risk prediction and potentially mitigation strategies.  Risks 
have not been denied and indeed increasing risks have been clearly communicated through a regularly 
updated physician website.(Biogen) Parties maintaining that patients should have the opportunity to 
make decisions including those where they assume substantial risks in hopes of unique benefits will be 
satisfied.  Others who want our regulatory systems to shield patients from very significant risks that may 
exceed the special benefits could wish for more stringent controls for such drugs.  Regardless, ongoing 
commitment by professionals to understand and communicate the nuanced and difficult decision of 
how to weigh benefit and risk so that patients can make the right choice is critical. Our healthcare 
system must therefore support physician’s time invested in this critical part of health care, and the 
importance of controlling the conflicts of interest that might influence physician’s recommendation in 
any way that is not focused on seeking the best outcome for patients and therefore for society. Perhaps 
the best pathway forward would be to better mitigate the PML risk for the patients by finding better 
tools to define exactly those patients at greatest risk7. The plan that is currently in use is a good start but 
with 8-10 new PML cases arising per month over the last decade, additional parameters should be 
explored. That is another challenge that should not need another decade to resolve.    
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While the view from the rear view mirror is clarifying, the view ahead has the clarity of a decade of 
experience that should be considered by the regulators and others to engage in a new discussion. 
Making a valuable therapy for MS safer should be the goal achieved by all the stakeholders.  
 
During the initial adjudication process, it became clear in discussions that the 3 index cases were not the 
end but the beginning of PML cases associated  with natalizumab therapy.    
 
 
